A Phase 4 interventional study of Tramadol/Paracetamol (APAP) and Non-Tramadol/APAP in Osteoarthritis, sponsored by Janssen Pharmaceutica. Completed at 1 site in Philippines. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-02-12.
Sponsored by Janssen Pharmaceutica (part of Johnson & Johnson) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies testing acetaminophen in Osteoarthritis — none open to participants now, none under way, none of them phase 3. Acetaminophen · Osteoarthritis.
Among the 14 studies testing acetaminophen in Osteoarthritis, this one is the 3rd largest by enrollment, is one of 2 that started in 2007, is one of 7 in phase 4, and was the 10th registered.
2,975 studies on the registry are indexed under Osteoarthritis; 435 are open to participants now.
Browse Osteoarthritis studies →None of the 14 studies testing acetaminophen in Osteoarthritis is open now. The open studies under Osteoarthritis, anywhere →
Acetaminophen: first FDA approval 1968 (NEOPAP). What it is approved for, and how studies give it, is on its page →
Of the 285 Osteoarthritis studies recruiting now, 157 (55%) set no upper age limit and 71 (25%) stop at 75 or younger; 22 take children under 18; 30 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 2 · Phase 3 4 · Phase 4 7
First in 2000; this study’s year is marked. 2 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 473 is above the median of 80 across 2,239 interventional studies indexed under Osteoarthritis.
Median enrollment 79 across the 14 interventional studies. Of the 11 that completed or were terminated, 5 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 14 have an industry lead sponsor. The 10 most frequent:
This study is registered under Janssen Pharmaceutica, one of the names counted as Johnson & Johnson. Under that name alone:
Janssen Pharmaceutica is the lead sponsor of 16 studies on the registry; none are open to participants now.
88 studies in Osteoarthritis by Johnson & Johnson: 1 open now, 3 under way, none of them phase 3. Of 84 finished, 26 (31%) have results posted.
Among the 88 studies in Osteoarthritis by Johnson & Johnson, this one is the 13th largest by enrollment of the 79 interventional ones that give a count, is one of 7 that started in 2007, is one of 32 in phase 4, and was the 62nd registered.
Johnson & Johnson’s Osteoarthritis studies by the year they started, since 1997.
None of the studies under way reaches primary completion within a year.
Among the 14 studies testing acetaminophen in Osteoarthritis, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Johnson & Johnson’s 88 in Osteoarthritis:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy, safety and effects on Quality of Life (QOL) of tramadol/paracetamol (APAP) as an add-on therapy (medication taken in addition to another medication) in Filipino participants with chronic (lasting a long time) osteoarthritis (disorder, which is seen mostly in older persons, in which the joints become painful and stiff).
This is an open-label (all people know the identity of the intervention), randomized (study drug assigned by chance), controlled study to evaluate the efficacy, safety and effects on QOL of tramadol/APAP as an add-on therapy in Filipino participants suffering from chronic pain because of chronic osteoarthritis. Participants will be randomly assigned to 2 groups: tramadol/APAP group and non tramadol/APAP group. Participants in tramadol/APAP group will receive celecoxib 200 milligram (mg) and fixed dose combination of tramadol (37.5 mg)/APAP (325 mg) as add on therapy, while the participants in non-tramadol/APAP group will receive celecoxib 200 mg only. The total duration of the study will be 4 weeks. The participants in both the groups will be given celecoxib 200 mg once daily for 4 weeks. In addition, the participants in the tramadol/APAP group will be given add-on tramadol/APAP doses 3 times a day for 4 weeks. Participants will be asked to return for follow-up at Weeks 2 and 4. Efficacy will be assessed using 100 millimeter (mm) Visual Analog Scale (VAS) while QOL will be assessed using the Oswestry Disability Index (ODI). Participant safety will be monitored throughout the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Tramadol/Paracetamol (APAP)
Drug: Non-Tramadol/APAP
Drug page: Acetaminophen
Celecoxib 200 milligram (mg) once daily for 4 weeks and fixed dose combination of Tramadol 37.5 mg/Paracetamol 325 mg thrice daily for 4 weeks as add-on therapy.
Celecoxib 200 mg alone once daily for 4 weeks.
Change From Baseline in Visual Analogue Scale for Pain (VAS-pain) Score at Week 2
VAS is a 100 millimeter (mm) scale. Intensity of pain range: 0 mm=no pain to 100 mm=worst possible pain. Change=scores at observation minus score at baseline. An increase in score from baseline represented disease progression and/or joint worsening, no change represented halting of disease progression, and a decrease represented improvement.
Time frame: Baseline and Week 2
Change From Baseline in VAS-pain Score at Week 4
VAS is a 100 mm scale. Intensity of pain range: 0 mm=no pain to 100 mm=worst possible pain. Change=scores at observation minus score at Baseline. An increase in score from baseline represented disease progression and/or joint worsening, no change represented halting of disease progression, and a decrease represented improvement.
Time frame: Baseline and Week 4 Last Observation Carried Forward (LOCF)
Change From Baseline in Oswestry Disability Index (ODI) Score at Week 2
The ODI is a low back pain-specific, validated instrument that consists of questions related to limitations in performing specific activities of daily living and 1 question related to pain intensity. The ODI is a self-administered questionnaire that is usually completed in less than 5 minutes. The ODI consists of 10 sections. Each section consists of 6 statements ranked from 0 to 5 (0=good to 5=worse). A higher score represents greater disability.
Time frame: Baseline and Week 2
Change From Baseline in ODI Score at Week 4
The ODI is a low back pain-specific, validated instrument that consists of questions related to limitations in performing specific activities of daily living and 1 question related to pain intensity. The ODI is a self-administered questionnaire that is usually completed in less than 5 minutes. The ODI consists of 10 sections. Each section consists of 6 statements ranked from 0 to 5 (0=good to 5=worse). A higher score represents greater disability.
Time frame: Baseline and Week 4 (LOCF)
Percentage of Participants Who Discontinued Because of Rescue Medication
Rescue medications are medicines that may be administered to the participants when the efficacy of the study drug is not satisfactory, or the effect of the study drug is too great and is likely to cause a hazard to the participant, or to manage an emergency situation.
Time frame: Baseline up to Week 4
Time to Discontinuation Because of Rescue Medication
Rescue medications are medicines that may be administered to the participants when the efficacy of the study drug is not satisfactory, or the effect of the study drug is too great and is likely to cause a hazard to the participant, or to manage an emergency situation.
Time frame: Baseline up to Week 4
| Milestone | Tramadol/Paracetamol (APAP) | Non-Tramadol/APAP |
|---|---|---|
| Started | 242 | 231 |
| Completed | 206 | 195 |
| Not completed | 36 | 36 |
| Withdrew: Participant needed rescue medication | 1 | 5 |
| Withdrew: Protocol violation | 1 | 0 |
| Withdrew: Withdrawal by subject | 2 | 3 |
| Withdrew: Lost to follow-up | 23 | 22 |
| Withdrew: Lack of efficacy | 1 | 1 |
| Withdrew: Adverse event | 8 | 5 |
VAS is a 100 millimeter (mm) scale. Intensity of pain range: 0 mm=no pain to 100 mm=worst possible pain. Change=scores at observation minus score at baseline. An increase in score from baseline represented disease progression and/or joint worsening, no change represented halting of disease progression, and a decrease represented improvement.
| mm | Tramadol/Paracetamol (APAP) | Non-Tramadol/APAP |
|---|---|---|
| Baseline | 71.86 ± 13.485 | 68.03 ± 13.77 |
| Change at Week 2 | -29.721 ± 16.936 | -21.972 ± 12.906 |
VAS is a 100 mm scale. Intensity of pain range: 0 mm=no pain to 100 mm=worst possible pain. Change=scores at observation minus score at Baseline. An increase in score from baseline represented disease progression and/or joint worsening, no change represented halting of disease progression, and a decrease represented improvement.
| mm | Tramadol/Paracetamol (APAP) | Non-Tramadol/APAP |
|---|---|---|
| Change From Baseline in VAS-pain Score at Week 4 | -45.027 ± 19.963 | -34.266 ± 15.665 |
The ODI is a low back pain-specific, validated instrument that consists of questions related to limitations in performing specific activities of daily living and 1 question related to pain intensity. The ODI is a self-administered questionnaire that is usually completed in less than 5 minutes. The ODI consists of 10 sections. Each section consists of 6 statements ranked from 0 to 5 (0=good to 5=worse). A higher score represents greater disability.
No measurements were reported for this outcome.
The ODI is a low back pain-specific, validated instrument that consists of questions related to limitations in performing specific activities of daily living and 1 question related to pain intensity. The ODI is a self-administered questionnaire that is usually completed in less than 5 minutes. The ODI consists of 10 sections. Each section consists of 6 statements ranked from 0 to 5 (0=good to 5=worse). A higher score represents greater disability.
| units on a scale | Tramadol/Paracetamol (APAP) | Non-Tramadol/APAP |
|---|---|---|
| Baseline | 58.24 ± 17.034 | 57.23 ± 16.780 |
| Change at Week 4 (LOCF) | -19.102 ± 15.103 | -15.177 ± 13.328 |
Rescue medications are medicines that may be administered to the participants when the efficacy of the study drug is not satisfactory, or the effect of the study drug is too great and is likely to cause a hazard to the participant, or to manage an emergency situation.
| percentage of participants | Tramadol/Paracetamol (APAP) | Non-Tramadol/APAP |
|---|---|---|
| Percentage of Participants Who Discontinued Because of Rescue Medication | 0.41 | 2.16 |
Rescue medications are medicines that may be administered to the participants when the efficacy of the study drug is not satisfactory, or the effect of the study drug is too great and is likely to cause a hazard to the participant, or to manage an emergency situation.
No measurements were reported for this outcome.
Collected over From signing of informed consent until 30 days after the last dose of study medication. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Tramadol/Paracetamol (APAP) | — | 1/242 (0.4%) | 19/242 (7.9%) |
| Non-Tramadol/APAP | — | 1/231 (0.4%) | 10/231 (4.3%) |
| Event | Tramadol/Paracetamol (APAP) | Non-Tramadol/APAP |
|---|---|---|
| Vaginal BleedingGeneral disorders | 0/242 | 1/231 |
| Severe HypertensionGeneral disorders | 1/242 | 0/231 |
| Generalized Body RashesGeneral disorders | 1/242 | 0/231 |
| Dizziness / NauseaGeneral disorders | 1/242 | 0/231 |
| Event | Tramadol/Paracetamol (APAP) | Non-Tramadol/APAP |
|---|---|---|
| Dizziness / NauseaGeneral disorders | 10/242 | 2/231 |
| DrowsinessGeneral disorders | 5/242 | 0/231 |
| Abdominal PainGeneral disorders | 4/242 | 1/231 |
| VertigoGeneral disorders | 0/242 | 2/231 |
| TachycardiaGeneral disorders | 0/242 | 1/231 |
| DyspepsiaGeneral disorders | 0/242 | 1/231 |
| PalpitationGeneral disorders | 0/242 | 1/231 |
| Leg HeavinessGeneral disorders | 0/242 | 1/231 |
| HeadacheGeneral disorders | 0/242 | 1/231 |
| FlatulenceGeneral disorders | 1/242 | 1/231 |
| Age Continuous(years) | Tramadol/Paracetamol (APAP) | Non-Tramadol/APAP | Total |
|---|---|---|---|
| Mean | 61.991 ± 12.084 | 62.40 ± 12.437 | 62.19 ± 12.248 |
| Sex/Gender, Customized(participants) | Tramadol/Paracetamol (APAP) | Non-Tramadol/APAP | Total |
|---|---|---|---|
| Female | 171 | 177 | 348 |
| Male | 69 | 53 | 122 |
| Unknown | 2 | 1 | 3 |
The record gives a start of Oct 2007, a primary completion of May 2008 and a completion of May 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2013, 4 years 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Acetaminophen